Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel indications of mannan-binding lectin (MBL) in the treatment of immunocompromised individuals

A mannan, immunocompromised technology, applied in drug combinations, medical preparations containing active ingredients, peptide/protein components, etc.

Inactive Publication Date: 2007-01-24
斯蒂芬·蒂尔 +1
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

MBL deficiency is associated with susceptibility to various infections

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel indications of mannan-binding lectin (MBL) in the treatment of immunocompromised individuals
  • Novel indications of mannan-binding lectin (MBL) in the treatment of immunocompromised individuals

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0032] To date, MBL has been used to treat MBL deficiency, which is defined as any level below 50 ng / ml, or more often below 10 ng / ml serum, a cut-off level typically associated with various MBL detection assays. The level of sensitivity was consistent, so this level was set at a level of MBL that was substantially undetectable by various assays in the prior art.

[0033] The present invention shows that infection in immunocompromised individuals can be prevented and / or treated independently of their serum MBL levels. Especially when MBL is administered in immunocompromised individuals whose MBL levels exceed 50 ng / ml serum, infection in these individuals can be prevented. In addition, individuals with MBL levels greater than 75 ng / ml serum may require treatment, such as individuals with MBL levels greater than 100 ng / ml serum, and individuals with MBL levels greater than 150 ng / ml serum.

[0034] Infections can also be treated with MBL by administering MBL to such individual...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention relates to the use of a composition comprising at least one mannan-binding lectin (MBL) subunit, or at least one mannan-binding lectin (MBL) oligomer comprising the at least one mannan-binding lectin (MBL) subunit, in the manufacture of a medicament for prophylaxis and / or treatment of infection. In particular the invention relates to prophylaxis and / or treatment of infectionin an individual having an immunocompromised condition; and / or an individual being at risk of acquiring an immunocompromised condition resulting from a medical treatment. The present invention is particularly relevant for prophylaxis and / or treatment of infection in individuals suffering from neutropenia, in particular as prophylaxis and / or treatment of infection in individuals receiving or goingto receive chemotherapy or similar treatment. The individuals may be treated independent on their serum MBL level, and it has been shown that in particular individuals having a serum MBL level in therange of from 50 ng / ml serum to 500 ng / ml serum may benefit from the prophylaxis and / or treatment.

Description

[0001] This application is a branch of the patent application with the application number 00809714.3, the application date is May 10, 2000, and the invention title is "New significance of mannan-binding lectin (MBL) in the treatment of immunocompromised individuals". case application. field of invention [0002] The present invention relates to the use of subunits and oligomers of mannan-binding lectin (MBL) in the prophylactic and / or curative treatment of immunocompromised individuals. Background of the invention [0003] Multiple groups of lectins, carbohydrate-binding proteins, are known in the human body. One of these groups is the C-type lectins. C-type lectins contain a calcium-dependent carbohydrate recognition domain (C-type CRD) 1 . Mannan-binding lectin (MBL) (synonym for mannose-binding lectin), mannan-binding protein, or mannose-binding protein (MBP) belongs to the subgroup of C-type lectins called collectins. group because these soluble proteins consist of s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61P31/00A61P37/04
Inventor 斯蒂芬·蒂尔詹斯·C·詹斯尼厄斯
Owner 斯蒂芬·蒂尔
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com